DaVita Total Liabilities and Share Holders Equity 2010-2024 | DVA
DaVita total liabilities and share holders equity from 2010 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
- DaVita total liabilities and share holders equity for the quarter ending September 30, 2024 was $17.504B, a 3.4% increase year-over-year.
- DaVita total liabilities and share holders equity for 2023 was $16.894B, a 0.2% decline from 2022.
- DaVita total liabilities and share holders equity for 2022 was $16.928B, a 1.13% decline from 2021.
- DaVita total liabilities and share holders equity for 2021 was $17.121B, a 0.78% increase from 2020.
DaVita Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023 |
$16,894 |
| 2022 |
$16,928 |
| 2021 |
$17,121 |
| 2020 |
$16,989 |
| 2019 |
$17,311 |
| 2018 |
$19,110 |
| 2017 |
$18,975 |
| 2016 |
$18,756 |
| 2015 |
$18,515 |
| 2014 |
$17,617 |
| 2013 |
$17,099 |
| 2012 |
$16,015 |
| 2011 |
$8,904 |
| 2010 |
$8,114 |
| 2009 |
$7,558 |
DaVita Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-09-30 |
$17,504 |
| 2024-06-30 |
$17,026 |
| 2024-03-31 |
$17,431 |
| 2023-12-31 |
$16,894 |
| 2023-09-30 |
$16,929 |
| 2023-06-30 |
$16,959 |
| 2023-03-31 |
$16,728 |
| 2022-12-31 |
$16,928 |
| 2022-09-30 |
$16,962 |
| 2022-06-30 |
$17,101 |
| 2022-03-31 |
$17,087 |
| 2021-12-31 |
$17,121 |
| 2021-09-30 |
$17,634 |
| 2021-06-30 |
$17,810 |
| 2021-03-31 |
$17,647 |
| 2020-12-31 |
$16,989 |
| 2020-09-30 |
$17,047 |
| 2020-06-30 |
$19,305 |
| 2020-03-31 |
$17,596 |
| 2019-12-31 |
$17,311 |
| 2019-09-30 |
$17,452 |
| 2019-06-30 |
$19,931 |
| 2019-03-31 |
$22,606 |
| 2018-12-31 |
$19,110 |
| 2018-09-30 |
$19,358 |
| 2018-06-30 |
$19,436 |
| 2018-03-31 |
$18,942 |
| 2017-12-31 |
$18,975 |
| 2017-09-30 |
$19,013 |
| 2017-06-30 |
$19,342 |
| 2017-03-31 |
$19,388 |
| 2016-12-31 |
$18,756 |
| 2016-09-30 |
$18,926 |
| 2016-06-30 |
$18,692 |
| 2016-03-31 |
$18,514 |
| 2015-12-31 |
$18,515 |
| 2015-09-30 |
$18,895 |
| 2015-06-30 |
$18,947 |
| 2015-03-31 |
$18,367 |
| 2014-12-31 |
$17,617 |
| 2014-09-30 |
$18,101 |
| 2014-06-30 |
$17,926 |
| 2014-03-31 |
$17,398 |
| 2013-12-31 |
$17,099 |
| 2013-09-30 |
$16,827 |
| 2013-06-30 |
$16,456 |
| 2013-03-31 |
$16,413 |
| 2012-12-31 |
$16,015 |
| 2012-09-30 |
$10,824 |
| 2012-06-30 |
$9,255 |
| 2012-03-31 |
$9,157 |
| 2011-12-31 |
$8,904 |
| 2011-09-30 |
$8,707 |
| 2011-06-30 |
$8,193 |
| 2011-03-31 |
$8,323 |
| 2010-12-31 |
$8,114 |
| 2010-09-30 |
$7,627 |
| 2010-06-30 |
$7,578 |
| 2010-03-31 |
$7,692 |
| 2009-12-31 |
$7,558 |
| 2009-09-30 |
$7,538 |
| 2009-06-30 |
$7,441 |
| 2009-03-31 |
$7,235 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$12.098B |
$12.140B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
